This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Clinical trial NCT03573544 · TERMINATED

Trial details

NCT number: NCT03573544
Sponsor: OBI Pharma, Inc
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Solid Tumors Locally Advanced Solid Tumors

Start date: 2018-05-07
Primary completion: 2022-04-07
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.